CMPS and MMED remain within ±8% of today's close through August absent a Phase 3 readout or M&A event.

CMPS and MMED are two companies developing psychedelic medicines that trade on the NASDAQ stock exchange. Without a major announcement — like final results from a large clinical trial or a buyout deal — there's no strong reason for their stock prices to swing sharply in either direction. This prediction says both stocks will end August within 8% of where they started, as long as no game-changing news drops.

Nothing in today's tape (LOIs, academic pilots) is a de-risking catalyst; institutions wait for topline data or deals. Ticker-anchored, near-term, and clearly falsifiable.